We presented a pandemic H1N1 2009 infl uenza virus infection in two pregnant women who were referred to the intensive care unit (ICU) with a rapidly progressive disease course. Both women had unremarkable past medical history. The fi rst woman had the symptoms of fever, cough, dyspnea and tachypnea lasting for four days. The second woman refused to take oseltamivir treatment. They were both referred to ICU with the diagnosis of pneumonia and acute respiratory distress syndrome. The second woman was intubated for two days in ICU. Both women showed a gradual improvement in their follow up and were discharged. Early admission, prompt diagnosis and early recourse to antiviral treatment gives better results in H1N1 infected pregnant women (Fig. 2 Pandemic H1N1 2009 infl uenza virus infection caused a widespread outbreak of respiratory infection. The virus, which originated in Mexico, spread globally to nearly 191 countries and territories worldwide. The novel virus contained a unique combination of gene segments that were not identifi ed before (1, 2).
Pandemic H1N1 2009 infl uenza virus infection caused a widespread outbreak of respiratory infection. The virus, which originated in Mexico, spread globally to nearly 191 countries and territories worldwide. The novel virus contained a unique combination of gene segments that were not identifi ed before (1, 2) .
The cases of the current pandemic presented with mild symptoms such as body aches, fatigue, chills, rhinorrhea, conjunctivitis, shortness of breath, headache and gastrointestinal (GI) symptoms. GI symptoms such as diarrhea and vomiting appeared more frequently than seasonal infl uenza. Pregnant women tend to present with fever, cough and/or sore throat besides these symptoms (3) . They experienced shortness of breath more often than nonpregnant cases.
During both interpandemic seasonal infl uenza and previous pandemics, it was found that pregnant women and fetus were at an increased risk for complications. During the period of April 15, 2009 to June 16, 2009, CDC reported 45 deaths from H1N1 infection; six (13 %) of these individuals were pregnant (4) . From April 23 to August 11, 2009, a total of 10 % of the 1088 patients who were hospitalized with or died from 2009 H1N1 infl uenza, as reported to the California Department of Public Health (CDPH), were pregnant (5). The CDC had implemented an enhanced surveillance for infection with H1N1 in pregnant women because of the concerns about the severity of the disease during pregnancy (3) .
In this report, we presented two pregnant women with pandemic H1N1 2009 infl uenza virus infection who were hospitalized in the three months of outbreak when the pandemic infl uenza cases peaked in our country.
Case 1
A 22-years-old woman at 16 weeks' gestation presented with the symptoms of fever, cough, sore throat, myalgia, dehydration, dyspnea and tachypnea, which was present for four days. She had also vaginal bleeding and pelvic pain for the last two days. Her body temperature was 39.6 ºC, blood pressure was 90/60 mmHg, heart rate was 112 beats per minute (bpm) and respiratory rate was 25 per minute. Oxygen saturation level was 95 % on room air on admission. The patient was a non-smoker and her past medical history was unremarkable. Chest auscultation revealed dullness, inspiratory crackles and rales. The patient was isolated from other pregnant patients for the evaluation of a probable H1N1 virus infection. Samples were taken for H1N1 virus testing from nose and throat. Vaginal bleeding was observed on pelvic examination. Ultrasonographic examination revealed an intrauterine pregnancy consistent with the gestational age. White blood cell count was 9x10 9 /L. Chest X-ray revealed a diffuse bilateral infi ltration ( Fig.  1) . After an increase in her vaginal bleeding and rupture of membranes, the pregnancy ended with abortion. The morphologic appearance of the fetus was normal. Although she was started on empiric therapy of oseltamivir (Tamifl u, Roche, Turkey) (75 mg, twice daily, PO) and antibiotic treatment of sulbactam-ampicillin (Duocid, Pfi zer, Turkey) (1 g, four times a day, i.v.) for the superimposed pneumonia, she had a rapidly progressive disease course. Oxygen saturation level decreased below 80 %. Arterial blood gas sampling revealed a PaO 2 of 67 mmHg. She was transferred to the intensive care unit (ICU). During her follow up in ICU, she continued to take the treatment together with oxygen supplementation and ipratropium bromide (Combivent, Boehringer Ingelheim, Turkey) inhalation therapy. Her oxygen saturation level was held around 85 % with nasal oxygen supplementation so she was not intubated. She clinically improved with this regimen. Laboratory results confi rmed the H1N1 virus infection by a real-time reverse transcriptase PCR. She was discharged on hospital day 10.
Case 2
A 34-years-old woman at 36 weeks' of gestation was hospitalized with the diagnosis of an intrauterine growth restriction, oligohydramnios and fl u-like symptoms. She presented with the symptoms of fever, cough, sore throat, myalgia and dehydration. Her body temperature was 39.2 ºC, blood pressure was 100/60 mmHg, pulse was 112 beats per minute (bpm) and respiratory rate was 22 per minute on admission. Oxygen saturation level was 96 % on room air. She was a non-smoker and her past medical history was unremarkable. She was isolated from other pregnant women and samples from nose and throat were taken to diagnose a possible H1N1 virus infection. White blood cell count was 6.8x10 9 /L on admission. She was offered to take oseltamivir, which she refused to use. Ultrasound examination revealed an intrauterine pregnancy consistent with 33-35 weeks' gestation and oligohydramnios. External fetal monitoring, which revealed an absent variability at fi rst, noted late decelerations on the fetal heart rate tracing soon after. Given this non reassuring fetal status, she delivered by an emergency cesarean. She delivered a female infant with the birth weight of 2320 g with Apgar scores of 8 at 1st min and 10 at 5th min. The newborn was normal with no evidence of infl uenza infection. After the delivery, the patient developed dyspnea and tachypnea. Chest X-ray revealed diffuse bilateral infi ltrations (Fig.  2) . Oxygen saturation level decreased to 88 %. Arterial blood gas sampling revealed a PaO 2 of 58.3 mmHg. She was referred to ICU. Laboratory results confi rmed H1N1 virus infection by a real-time reverse transcriptase PCR. Oseltamivir was added 36 hours after delivery to the empiric antibiotic therapy of sulbactam-ampicillin (1 g, four times a day, PO) for the superimposed pneumonia after the patient's approval. Ipratropium bromide inhalation therapy was initiated. She remained intubated for two days in ICU. The patient showed a gradual improvement in her follow up and was discharged on hospital day 10.
Discussion
We present two different cases of H1N1 infl uenza virus infection with superimposed pneumonia and acute respiratory distress syndrome. We hospitalized 23 additional cases with laboratory confi rmed H1N1 virus infection in our institution during three months of outbreak, from October to December, 2009. The diagnosis of infl uenza was confi rmed by 'Swine Infl uenza PCR Testing Kit', which was prepared by Centres for Disease Control and Prevention (CDC) and distributed by World Health Organization (WHO). The kits were available from the National Infl uenza Center in Turkey. Although these two patients followed a rapidly progressive disease course, most of the pregnant women exhibited mild disease process with a stable course. In a recent study involving large series of pregnant and postpartum patients who were hospitalized with or died from 2009 H1N1 infl uenza, 95 % of the pregnant patients were infected in the second or third trimester, and almost one fi fth required intensive care (6) .
The novel H1N1 2009 infl uenza virus is sensitive to neuraminidase inhibitors oseltamivir and zanamivir. The benefi t of treatment with these antiviral drugs outweighs its theoretical risk. Current CDC guidance suggests that antiviral treatment is recommended for groups at high risk for infl uenza complications from infection with H1N1 2009 infl uenza virus including pregnant women. The CDC recommends a prompt antiviral treatment of pregnant women with suspected or confi rmed 2009 H1N1 infl uenza, ideally within 48 hours after symptom onset (7) . Because of its systemic activity, the drug of choice for pregnant women is oseltamivir. It can reduce mortality in patients even when started more than 48 hours after the onset of symptoms (4) . The fi rst case in this report had symptoms for four days and the second case refused to take antiviral therapy because of concerns about the fetus. These factors caused a delay in the initiation of the treatment and might be responsible for the rapid progression of the disease. Early admission and prompt initiation of the antiviral therapy could have resulted in a shorter recovery period and better outcome in these cases.
Louie et al reported a continued high risk immediately after pregnancy in their study of H1N1 virus infection in pregnant, non pregnant and postpartum women (6) . A variety of cardiac, respiratory, hormonal, and immunologic changes that occur during pregnancy may contribute to an increased risk of infl uenza-related morbidity and mortality among pregnant women (8) . Although it is not known for how long after delivery these changes persist, some of them (i.e., immunologic alterations) might persist longer than others (e.g., decreased lung capacity due to uterine compression). In light of these emerging data, the CDC recently issued the revised guidelines, recommending a prompt initiation of antiviral treatment in patients with suspected or confi rmed infl uenza up to two weeks after delivery (7) .
The CDC has listed pregnant women as a priority group for vaccination, along with children and health care workers (9) . The pregnant women are at a higher risk for complications and can also potentially provide protection to infants who cannot be vaccinated via the transfer of maternal antibodies to the fetus. On September 15, 2009, four infl uenza vaccine manufacturers received the approval from the Food and Drug Administration (FDA) for their novel infl uenza A (H1N1) 2009 monovalent vaccines. Since 2009, H1N1 monovalent vaccine is manufactured according to the same processes that are used for the seasonal infl uenza vaccine, its safety profi le among pregnant women is expected to be similar to that of the seasonal infl uenza vaccine, which has consistently been shown to be safe during pregnancy (10).
Women with suspected or confi rmed infl uenza who are pregnant or who have delivered within the previous two weeks should receive an aggressive antiviral treatment and undergo close monitoring. Timely medical attention and early recourse to antiviral therapy is associated with a better outcome in H1N1 affected pregnant women. Fever and low oxygen saturation levels should alert the clinician about the development of a complication such as pneumonia and respiratory distress. Since pregnant women and their fetuses require an intensive care and monitoring, critically ill pregnant and postpartum women should be hospitalized in centres including the neonatal intensive care units, which can provide a higher level of care for both mother and the newborn.
